Literature DB >> 28593646

Cancer incidence and mortality: A cohort study in China, 2008-2013.

Rui Pan1, Meng Zhu1, Canqing Yu2, Jun Lv2, Yu Guo3, Zheng Bian3, Ling Yang4, Yiping Chen4, Zhibin Hu1, Zhengming Chen4, Liming Li2,3, Hongbing Shen1.   

Abstract

The National Central Cancer Registry of China (NCCR) was the only available source of cancer monitoring in China, even though only about 70% of cancer registration sites were qualified by now. In this study, based on a national large prospective cohort-the China Kadoorie Biobank (CKB), we aimed to provide additional cancer statistics and compare the difference of cancer burden between urban and rural areas of China. A total of 497,693 cancer-free participants aged 35-74 years were recruited and successfully followed up from 2004 to 2013 in 5 urban and 5 rural areas across China. Except for traditional registration systems, the national health insurance system and active follow-up were used to determine new cancer incidents and related deaths. The mortality-to-incidence ratio (MIR) was used to compare the differences of cancer burden between urban and rural areas of China. We found that cancer mortality coincided well between our cohort and NCCR, while the incidence was much higher in our cohort. Based on CKB, we found the MIR of all cancers was 0.54 in rural areas, which was approximately one-third higher than that in urban areas with 0.39. Cancer profiles in urban areas were transiting to Western distributions, which were characterized with high incidences of breast cancer and colorectal cancer; while cancers of the esophagus, liver and cervix uteri were still common in rural areas of China. Our results provide additional cancer statistics of China and demonstrate the differences of cancer burden between urban and rural areas of China.
© 2017 UICC.

Entities:  

Keywords:  cancer incidence; cancer mortality; cohort study; mortality-to-incidence ratio

Mesh:

Year:  2017        PMID: 28593646     DOI: 10.1002/ijc.30825

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  54 in total

1.  HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.

Authors:  Li Wei; Liang Tang; Haiyan Chang; Song Huo; Yan Li
Journal:  Hum Cell       Date:  2019-09-24       Impact factor: 4.174

2.  Important Role of Health Surveillance Systems in Community-Based Colorectal Cancer Screening.

Authors:  Ann Chao; Sudha Sivaram
Journal:  Oncologist       Date:  2018-07-26

3.  Serum Concentrations of 15 Elements Among Helicobacter Pylori-Infected Residents from Lujiang County with High Gastric Cancer Risk in Eastern China.

Authors:  Anla Hu; Li Li; Chuanlai Hu; Daoming Zhang; Chen Wang; Yan Jiang; Meng Zhang; Chunmei Liang; Wenjun Chen; Qingli Bo; Qihong Zhao
Journal:  Biol Trace Elem Res       Date:  2018-03-03       Impact factor: 3.738

Review 4.  Targeting E-cadherin expression with small molecules for digestive cancer treatment.

Authors:  Yizuo Song; Miaomiao Ye; Junhan Zhou; Zhiwei Wang; Xueqiong Zhu
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 5.  Social group disparities in the incidence and prognosis of oesophageal cancer.

Authors:  Shao-Hua Xie; Jesper Lagergren
Journal:  United European Gastroenterol J       Date:  2018-01-10       Impact factor: 4.623

Review 6.  Long non-coding RNA PVT1: Emerging biomarker in digestive system cancer.

Authors:  Dan-Dan Zhou; Xiu-Fen Liu; Cheng-Wei Lu; Om Prakash Pant; Xiao-Dong Liu
Journal:  Cell Prolif       Date:  2017-10-12       Impact factor: 6.831

7.  Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.

Authors:  Juncheng Dai; Jun Lv; Meng Zhu; Yuzhuo Wang; Na Qin; Hongxia Ma; Yong-Qiao He; Ruoxin Zhang; Wen Tan; Jingyi Fan; Tianpei Wang; Hong Zheng; Qi Sun; Lijuan Wang; Mingtao Huang; Zijun Ge; Canqing Yu; Yu Guo; Tong-Min Wang; Jie Wang; Lin Xu; Weibing Wu; Liang Chen; Zheng Bian; Robin Walters; Iona Y Millwood; Xi-Zhao Li; Xin Wang; Rayjean J Hung; David C Christiani; Haiquan Chen; Mengyun Wang; Cheng Wang; Yue Jiang; Kexin Chen; Zhengming Chen; Guangfu Jin; Tangchun Wu; Dongxin Lin; Zhibin Hu; Christopher I Amos; Chen Wu; Qingyi Wei; Wei-Hua Jia; Liming Li; Hongbing Shen
Journal:  Lancet Respir Med       Date:  2019-07-17       Impact factor: 30.700

8.  Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3.

Authors:  Yamei Hu; Fangfang Liu; Xuechao Jia; Penglei Wang; Tingxuan Gu; Hui Liu; Tingting Liu; Huifang Wei; Hanyong Chen; Jiuzhou Zhao; Ran Yang; Yingying Chen; Zigang Dong; Kangdong Liu
Journal:  Oncogene       Date:  2021-05-13       Impact factor: 9.867

9.  Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma.

Authors:  He Wang; Huiwen Wang; Wenyu Cui; Qiao Zhang; Jing Li; Qi Zhang
Journal:  Diagn Pathol       Date:  2021-06-11       Impact factor: 2.644

10.  Development and external validation of a breast cancer absolute risk prediction model in Chinese population.

Authors:  Yuting Han; Jun Lv; Canqing Yu; Yu Guo; Zheng Bian; Yizhen Hu; Ling Yang; Yiping Chen; Huaidong Du; Fangyuan Zhao; Wanqing Wen; Xiao-Ou Shu; Yongbing Xiang; Yu-Tang Gao; Wei Zheng; Hong Guo; Peng Liang; Junshi Chen; Zhengming Chen; Dezheng Huo; Liming Li
Journal:  Breast Cancer Res       Date:  2021-05-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.